The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a https://hassangesk888685.wikirecognition.com/1997573/retatrutide_vs_tirzepatide_a_comparative_analysis